View clinical trials related to Lung Neoplasms.
Filter by:The aim of this study is to gather insight into tumor-derived circulating extracellular vesicles-proteins in patients with newly diagnosed small cell lung cancer.
The goal of this clinical trial is to investigate if weekly symptom monitoring of patients with advanced lung cancer is associated with better survival and improved quality of life compared to standard follow-up. Each week, participants in the intervention group will be asked to respond to an electronic weekly questionnaire covering 11 items related to current health status.
The study's purpose is to understand the self-management needs of patients with NSCLC receiving targeted therapy, develop a disease self- management application (mHealth Application), and explore the effect of mHealth application on the self-efficacy and health status of patients receiving targeted therapy for NSCLC. This study adopts a two-group (pre-and-post-test) design experiment. This study is being conducted over a period of 3 years and is divided in two stages. This study enrolled patients with NSCLC in the outpatient clinic and ward of the Division of Chest Medicine in a northern medical center as the research participants. Stage 1 develop a disease self-management application and understands participants' needs by qualitative study. The participants are a purposive sample of 15-20 patients. Data discontinued when theme saturation is achieved. Stage 2 adopted convenient sampling to enroll 108 patients (54 in the experimental group and 54 in the control group) to evaluate the effectiveness of the disease self-management application. After participant's consent was obtained, this study performed the pre-test and randomized the participants. The experimental group received both routine care and the disease self-management App, while the control group received routine care and part of application. This study collected data before the patients received targeted therapy and in months 1, 3, 6, and 9 after treatment initiation.
To evaluate the clinical efficacy and safety of surufatinib combined with irinotecan in the second line treatment of small cell lung cancer.
This clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free survival in patients with extensive-stage small cell lung cancer (ES-SCLC) with liver metastases. The main questions it aims to answer are: - In patients with ES-SCLC with liver metastases, can bevacizumab in combination with atezolizumab and chemotherapy prolong the length of time that the cancer does not progress? - Is bevacizumab safe and tolerable when combined with atezolizumab and chemotherapy in patients with ES-SCLC and liver metastases? The study treatment includes two phases: - Induction phase: bevacizumab will be administered in combination with atezolizumab and chemotherapy on a 21-day cycle for four cycles. - Maintenance: atezolizumab and bevacizumab will be administered every 21 days for up to 12 months, or until unacceptable toxicity or disease progression. Participants will undergo blood tests every 3 weeks and tumor assessments every 6 weeks.
This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving treatment with Osimertinib
A clinical trial to assess the safety and efficacy of genetically-engineered Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been inhibited using CRISPR gene editing for the treatment of Metastatic Non-small Cell Lung Cancer (NSCLC).
Micro-computed tomography (micro-CT) is a novel biomedical non-destructive, slide-free digital imaging modality, which enables the rapid acquisition of accurate high-resolution, volumetric images of intact surgical tissue specimens. This imaging modality provides microscopic level of detail of intact tissues in three-dimensions without requiring any specimen preparation. Its non-destructive nature and the ongoing enhancement of imaging resolution and contrast renders micro-CT imaging particularly well suited for microanatomic studies in basic research across a wide range of interventional medical disciplines, including oncology. Our proposal concerns a multidisciplinary basic research effort which aims to facilitate the effective identification of different -and maybe challenging to differentiate- lung cancer patterns based on 3D X-ray histology. As an alternative for the use of hematoxylin & eosin (H&E) slides, optimized micro-CT scanning of soft tissues emerges as a promising tool to enable non-invasive 3D X-ray histology of formalin-fixed and paraffin-embedded (FFPE) lung cancer specimens. The objective of our proposal is to offer novel insights into the complex architecture of each lung cancer subtype after imaging FFPE surgical specimens, resected from lung cancer surgeries. The investigators aim to generate 3D datasets of FFPE lung cancer tissues which will be combined with the corresponding conventional 2D histology slides. Our study will be also adequately empowered to identify particular differences in morphometric measurements according to each particular lung cancer growth pattern. Finally, this proposal aims to delineate the different 3D microanatomy and morphology of some patterns that are challenging to interpret and differentiate through traditional 2D histological evaluation, such as papillary and lepidic adenocarcinoma growth patterns. Classification of the histological subtypes based on 2D histology sections can be ambiguous, as shown by suboptimal inter-observer consensus when determining predominant histological subtypes in FFPE lung adenocarcinoma tissue specimens. Hence, micro-CT-based 3D imaging of the lung specimens could aid classification of histological subtypes by providing more comprehensive sampling of the entire tissue block and yielding detail relevant for subtype classification that might not be visible in 2D sections alone.
In this monocentric randomized controlled trial, 120 potential non small cell lung cancer (NSCLC) patients for which tissue diagnosis and material for next generation sequencing (NGS) is required for clinical management will be approached the day of their endobronchial ultrasound to participate in the study. They will be randomized to 2 vs 3 passes/lymph node and will all undergo liquid biopsy. The co-primary outcomes are 1)the rate of obtention of adequate material for NGS testing with 2 vs 3 passes/lymph node and 2)the percentage of patients for which liquid biopsy allows to identify clinically pertinent findings not available from tissue biopsy
This is a first-in-human clinical trial evaluating the safety of an alpha-radiation treatment (Lead-212 labelled Pentixather) in patients who have been diagnosed with, and previously treated, for atypical carcinoid lesions of the lung.